Aripiprazole
Product Images NDC 50090-5839

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 50090-5839). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Figure1)

A chart titled 'Effect of Other Drugs on Aripiprazole' showing aripiprazole fold change and 90% confidence intervals in pharmacokinetic parameters AUC and Cmax. It compares the influence of CYP3A4 inhibitors, CYP2D6 inhibitors, CYP3A4 inducers, gastric acid blockers, and other drugs like valproate, lithium, and lorazepam relative to reference values without interacting drugs.*

FDA Label Image

Figure2 (Figure2)

A pharmacokinetic chart titled 'Effect of Other Drugs on Aripiprazole' showing dehydro-aripiprazole fold change and 90% confidence intervals. The x-axis represents change relative to reference without interacting drug (range 0 to 3). The y-axis lists different drug types including CYP3A4 inhibitors, CYP2D6 inhibitors, CYP3A4 inducers, gastric acid blockers, and others, with fold change data points for AUC and Cmax for each drug interaction.*

FDA Label Image

Figure3 (Figure3)

A chart titled 'Effect of Aripiprazole on Other Drugs' showing fold change and 90% confidence intervals. The x-axis represents change relative to reference without interacting drug, ranging from 0.0 to 3.0. The y-axis lists various drugs and pharmacokinetic parameters (Dextromethorphan, S-warfarin, INR, Omeprazole, Lamotrigine, Valproate, Lithium, Lorazepam, Venlafaxine, O-desmethylvenlafaxine) and associated measures like DMRP, AUC, Cmax. Data points with error bars illustrate the fold change effects of Aripiprazole on these drugs' pharmacokinetics.*

FDA Label Image

Figure4 (Figure4)

A scatter plot titled 'Aripiprazole Fold Change and 90% CI' showing pharmacokinetic (PK) changes, specifically area under the curve (AUC) and maximum concentration (Cmax), across special populations. Categories include CYP2D6 metabolizer status, gender, age groups, hepatic impairment degrees, and severe renal impairment. Error bars indicate confidence intervals, and the x-axis represents change relative to a reference.*

FDA Label Image

Figure5 (Figure5)

A pharmacokinetic chart titled 'Dehydro-Aripiprazole Fold Change and 90% CI' showing fold change and confidence intervals for AUC and Cmax values. It compares variables including CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment relative to reference values.*

FDA Label Image

Structure (Structure)

Chemical structure diagram of the active ingredient Aripiprazole, showing its molecular connectivity with labeled elements including chlorine atoms.*

FDA Label Image

Camberlogo (Camber Logo)

FDA Label Image

Figure 6 (Figure 6)

A Kaplan-Meier curve chart depicting the proportion of subjects with relapse over days from randomization for Aripiprazole and placebo groups. The graph includes a time axis (days up to 182) and a relapse proportion axis (0 to 1). The number of subjects at risk is displayed below the time axis for both groups.*

FDA Label Image

Figure 7 (Figure 7)

A Kaplan-Meier plot showing the proportion of subjects with relapse over time in days from randomization, comparing Aripiprazole to placebo. The graph includes a risk table indicating the number of subjects at risk at various time points for both Aripiprazole and placebo groups.*

FDA Label Image

Figure 8 (Figure 8)

A Kaplan-Meier plot depicting the proportion with relapse over days from randomization for Aripiprazole compared to placebo. The graph shows time on the x-axis (days) and proportion with relapse on the y-axis, including the number of subjects at risk for each group across time points.*

FDA Label Image

Label Image (Lbl500905839)

Packaging label for Aripiprazole 5 mg tablets by A-S Medication Solutions. The label shows the NDC 50090-5839-0, product number 6703-0, storage instructions at 68 to 77 degrees Fahrenheit, and a package count of 30 tablets. A QR code and manufacturer address in Libertyville, IL are also visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.